Brief: Cymabay Announces FDA Acceptance Of NDA And Priority Review For Seladelpar

CymaBay Therapeutics

12/02/2024 14:56

Feb 12 (Reuters) - Cymabay Therapeutics Inc  CBAY.O :
    * CYMABAY ANNOUNCES FDA ACCEPTANCE OF NDA AND PRIORITY
REVIEW FOR
SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
    * FDA HAS GRANTED PRIORITY REVIEW WITH A TARGET PDUFA DATE
OF
AUGUST 14
    * FDA NOTIFIED CO IT IS NOT CURRENTLY PLANNING TO HOLD
ADVISORY
COMMITTEE MEETING TO DISCUSS APPLICATION

Source text for Eikon:  ID:nPn3R2psYa 
Further company coverage:  CBAY.O 

 ((Reuters.Briefs@thomsonreuters.com;))